Once-Daily Opicapone Adds ‘On Time’ in PD Phase 3 Studies

Once-Daily Opicapone Adds ‘On Time’ in PD Phase 3 Studies
A new COMT inhibitor in development with more convenient dosing is evaluated for safety and efficacy in people with Parkinson's disease and motor fluctuations. Medscape Medical News ... read more
Source: MedscapePublished on 2019-05-06